One year in review
Axial spondyloarthritis: one year in review 2023
F. Fattorini1, S. Gentileschi2, C. Cigolini3, R. Terenzi4, A.P. Pata5, L. Esti6, L. Carli7
- Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
- Department of Medical Sciences, Surgery and Neurosciences, Rheumatology Unit, University of Siena, Italy.
- Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
- SOC Reumatologia, USL Toscana Centro, Firenze, Italy.
- Department of Medical Sciences, Surgery and Neurosciences, Rheumatology Unit, University of Siena, Italy.
- Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
- Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy. 81clinda@gmail.com
CER17273
2023 Vol.41, N°11
PI 2142, PF 2150
One year in review
Free to view
(click on article PDF icon to read the article)
PMID: 37965699 [PubMed]
Received: 05/11/2023
Accepted : 09/11/2023
In Press: 14/11/2023
Published: 14/11/2023
Abstract
Axial spondyloarthritides (axSpA) are a group of systemic autoimmune diseases, characterised by an inflammatory involvement of the axial skeleton, which, in the earlier phases, cannot be detected by conventional radiology, but only by magnetic resonance imaging, thus defining the so-called non-radiographic axSpA (nr-axSpA). The initial osteitis then tends to complicate into bone reabsorption and aberrant bone deposition, which then determines the ankylosis of the axial skeleton in the latest phases of the disease. Peripheral joints may also be affected, enthesitis being its more characteristic manifestation. The radiographic form corresponds to ankylosing spondylitis which, with psoriatic arthritis, is the best-known subtype of SpA. AxSpA are rarely associated to laboratory abnormalities and are usually complicated by the presence of both extra-articular manifestations (particularly acute anterior uveitis, psoriasis and inflamatory bowel disease) and comorbidities, with a subsequent higher risk for patients of an impaired quality of life. In this paper we reviewed the literature on axSpA of 2021 and 2022 (Medline search of articles published from 1st January 2021 to 31st December 2022).
